Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Sulphasalazine lung.

T F Tydd

    The Medical Journal of Australia
    |April 17, 1976
    PubMed
    Summary
    This summary is machine-generated.

    Sulphasalazine can cause a rare lung condition called pulmonary eosinophilia. This review examines known cases of sulphasalazine-induced lung disease in the medical literature.

    Related Experiment Videos

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Nutritional megaloblastic anaemia in a young woman.

    The Medical journal of Australia·1981
    Same author

    Letter: Muscle biopsy in Crohn's disease.

    Lancet (London, England)·1974
    Same author

    Pyloric stenosis presenting with halitosis.

    British medical journal·1974
    See all related articles

    Area of Science:

    • Pulmonary Medicine
    • Pharmacology

    Background:

    • Sulphasalazine is a medication used to treat inflammatory bowel disease and rheumatoid arthritis.
    • Adverse drug reactions can affect multiple organ systems, including the lungs.

    Observation:

    • A case of pulmonary eosinophilia occurred in a patient treated with sulphasalazine.
    • Pulmonary eosinophilia is a rare but serious complication.

    Findings:

    • This report reviews the existing world literature on sulphasalazine-induced lung disease.
    • The review aims to consolidate information on this rare adverse effect.

    Implications:

    • Increased awareness of sulphasalazine-induced lung disease among clinicians is warranted.
    • Prompt recognition and management are crucial for patient outcomes.